Ascendis Pharma (NASDAQ: ASND) adds shares after warrant exercises

Rhea-AI Filing Summary

Ascendis Pharma A/S reports the closing of an exercise window for its outstanding warrants linked to ordinary shares. During this period, warrant holders exercised rights resulting in registered share capital increases of nominal DKK 399,438, bringing total share capital to nominal DKK 62,376,846.

The company issued 399,438 new ordinary shares against average cash consideration of approximately USD $92.10 per share, based on the DKK-USD exchange rate on March 30, 2026. Ascendis amended its articles of association to reflect the higher share capital, and the updated articles are attached as an exhibit.

Key Figures

New shares issued: 399,438 shares Capital increase: DKK 399,438 nominal Total share capital: DKK 62,376,846 nominal +1 more

4 metrics

New shares issued 399,438 shares Issued upon warrant exercises during the exercise window

Capital increase DKK 399,438 nominal Increase in registered share capital from warrant exercises

Total share capital DKK 62,376,846 nominal Total nominal share capital after registration of increases

Average consideration per share USD $92.10 per share Average cash consideration based on DKK-USD rate on March 30, 2026

Key Terms

Form 6-K, warrants, Articles of Association, registration statements on Form S-8, +1 more

5 terms

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

warrants financial

"an exercise window closed for the Company’s outstanding warrants exercisable"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Articles of Association regulatory

"The Company’s articles of association were amended accordingly and are attached"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

registration statements on Form S-8 regulatory

"incorporated by reference into the registration statements on Form S-8"

Form F-3 regulatory

"and Form F-3 (Registration Numbers 333-209336 and 333-282196)"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company” or “Ascendis”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Closing of Warrant Exercise Window

On March 30, 2026, an exercise window closed for the Company’s outstanding warrants exercisable for the Company’s ordinary shares, nominal value DKK 1. In connection with the exercises of certain of such warrants during this exercise window, the Company registered aggregate share capital increases of nominal DKK 399,438 with the Danish Business Authority, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 62,376,846 through the issuance of 399,438 ordinary shares against average cash consideration of approximately USD $92.10 per share, based on the DKK-USD exchange rate on March 30, 2026. The Company’s articles of association were amended accordingly and are attached hereto as Exhibit 1.1.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: March 30, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

FAQ

What did Ascendis Pharma A/S (ASND) announce in this Form 6-K?

Ascendis Pharma A/S announced that a warrant exercise window closed and certain outstanding warrants were exercised. This led to new ordinary shares being issued, an increase in nominal share capital, and amendments to the company’s articles of association to reflect the updated capital structure.

How many new Ascendis Pharma A/S shares were issued from the warrant exercises?

Ascendis Pharma A/S issued 399,438 new ordinary shares upon the exercise of certain outstanding warrants. These shares were created during the recently closed exercise window and contributed to a corresponding increase in the company’s nominal share capital recorded with the Danish Business Authority.

By how much did Ascendis Pharma A/S’s nominal share capital increase?

The company’s registered share capital increased by nominal DKK 399,438 in connection with the exercised warrants. Following this increase, Ascendis Pharma A/S’s total nominal share capital reached DKK 62,376,846, as reflected in its updated articles of association attached to the report.

What was the average cash consideration per Ascendis Pharma A/S share from the warrant exercises?

The average cash consideration for each new ordinary share issued upon warrant exercise was approximately USD $92.10. This figure is based on the DKK-USD exchange rate on March 30, 2026, the date when the warrant exercise window closed and related capital increases were registered.

How were Ascendis Pharma A/S’s articles of association affected by the warrant exercises?

Ascendis Pharma A/S amended its articles of association to incorporate the increased nominal share capital after the warrant exercises. The updated articles, reflecting the new total nominal share capital of DKK 62,376,846, are provided as Exhibit 1.1 and form part of the report’s documentation.

Are Ascendis Pharma A/S’s existing registration statements affected by this Form 6-K?

Yes. This Form 6-K is incorporated by reference into Ascendis Pharma A/S’s existing registration statements on Form S-8 and Form F-3. It becomes part of those registration statements from the filing date, unless later documents or reports supersede the information contained here.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 1.2 MB